The Select D [22] and the Caravaggio [26] trials excluded patients taking anystrong inducer or inhibitor of cytochrome P450 3A4 (CYP3A4) or P-glycoprotein(P-gp), and Hokusai VTE Cancer [20] excluded only patients using specific strongP-gp-inhibiting drugs with dose adjustment to edoxaban 30 mg once daily forpatients taking other strong P-gp inhibitors. This evidence concerns the gene CYP3A4 and cancer.